JP2004517850A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004517850A5 JP2004517850A5 JP2002552562A JP2002552562A JP2004517850A5 JP 2004517850 A5 JP2004517850 A5 JP 2004517850A5 JP 2002552562 A JP2002552562 A JP 2002552562A JP 2002552562 A JP2002552562 A JP 2002552562A JP 2004517850 A5 JP2004517850 A5 JP 2004517850A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- chr
- compound
- lower alkyl
- azepin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 29
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000000524 functional group Chemical group 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- -1 2-pyridin-3-yl-ethylamino Chemical group 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 239000003825 glutamate receptor antagonist Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- BVCRYZCZHIUGTH-UHFFFAOYSA-N triazine-4-carbonitrile Chemical compound N#CC1=CC=NN=N1 BVCRYZCZHIUGTH-UHFFFAOYSA-N 0.000 claims 2
- ZXJPSMOGMWHXJS-UHFFFAOYSA-N 3-(2-hydroxyethylamino)-5-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-1,2,4-triazine-6-carbonitrile Chemical compound OCCNC1=NN=C(C#N)C(N2CCC3=CC=CC=C3CC2)=N1 ZXJPSMOGMWHXJS-UHFFFAOYSA-N 0.000 claims 1
- KQUYZXMVISINLO-UHFFFAOYSA-N 3-(2-hydroxypropylamino)-5-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-1,2,4-triazine-6-carbonitrile Chemical compound CC(O)CNC1=NN=C(C#N)C(N2CCC3=CC=CC=C3CC2)=N1 KQUYZXMVISINLO-UHFFFAOYSA-N 0.000 claims 1
- IWNAADGICSAONH-UHFFFAOYSA-N 3-(cyclopropylmethylamino)-5-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-1,2,4-triazine-6-carbonitrile Chemical compound N1=C(N2CCC3=CC=CC=C3CC2)C(C#N)=NN=C1NCC1CC1 IWNAADGICSAONH-UHFFFAOYSA-N 0.000 claims 1
- XWVAIXMZXUFCNU-UHFFFAOYSA-N 3-hydrazinyl-5-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-1,2,4-triazine-6-carbonitrile Chemical compound NNC1=NN=C(C#N)C(N2CCC3=CC=CC=C3CC2)=N1 XWVAIXMZXUFCNU-UHFFFAOYSA-N 0.000 claims 1
- GTAFMXSTSWHFMA-UHFFFAOYSA-N 5-(2-hydroxyethylamino)-3-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrazine-2-carbonitrile Chemical compound OCCNC1=CN=C(C#N)C(N2CCC3=CC=CC=C3CC2)=N1 GTAFMXSTSWHFMA-UHFFFAOYSA-N 0.000 claims 1
- NFVBJKKYIDJBKV-UHFFFAOYSA-N 5-methyl-6-phenyl-3-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrazine-2-carbonitrile Chemical compound CC1=NC(N2CCC3=CC=CC=C3CC2)=C(C#N)N=C1C1=CC=CC=C1 NFVBJKKYIDJBKV-UHFFFAOYSA-N 0.000 claims 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 239000012038 nucleophile Substances 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- QBUAUORMGOVFIU-UHFFFAOYSA-N tert-butyl n-[2-[[6-cyano-5-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-1,2,4-triazin-3-yl]amino]ethyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCNC1=NN=C(C#N)C(N2CCC3=CC=CC=C3CC2)=N1 QBUAUORMGOVFIU-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00128329 | 2000-12-22 | ||
| PCT/EP2001/014527 WO2002051418A1 (en) | 2000-12-22 | 2001-12-11 | Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004517850A JP2004517850A (ja) | 2004-06-17 |
| JP2004517850A5 true JP2004517850A5 (enExample) | 2005-05-26 |
| JP4077319B2 JP4077319B2 (ja) | 2008-04-16 |
Family
ID=8170787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002552562A Expired - Fee Related JP4077319B2 (ja) | 2000-12-22 | 2001-12-11 | ｍＧｌｕＲ１アンタゴニストとしてのテトラヒドロ−（ベンゾ又はチエノ）−アゼピン−ピラジン及びトリアジン誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6586422B2 (enExample) |
| EP (1) | EP1345609B1 (enExample) |
| JP (1) | JP4077319B2 (enExample) |
| KR (1) | KR100545906B1 (enExample) |
| CN (1) | CN1260226C (enExample) |
| AR (1) | AR032379A1 (enExample) |
| AT (1) | ATE297734T1 (enExample) |
| AU (1) | AU2002216095B2 (enExample) |
| BR (1) | BR0116378A (enExample) |
| CA (1) | CA2432077C (enExample) |
| DE (1) | DE60111568T2 (enExample) |
| DK (1) | DK1345609T3 (enExample) |
| ES (1) | ES2243400T3 (enExample) |
| MX (1) | MXPA03005515A (enExample) |
| PT (1) | PT1345609E (enExample) |
| WO (1) | WO2002051418A1 (enExample) |
| ZA (1) | ZA200304557B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| CN101404882A (zh) * | 2006-01-19 | 2009-04-08 | 阿特西斯公司 | 作为5-羟色胺5-HT2c受体配体的噻吩基和吡咯基氮杂类及其用途 |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | アンジオテンシン調節による神経新生 |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| AU2007292848A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| KR101100864B1 (ko) * | 2009-06-12 | 2012-01-02 | 양준호 | 자동차 광택기용 광택패드 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3136654A1 (de) | 1981-09-16 | 1983-03-31 | Zahnradfabrik Friedrichshafen Ag, 7990 Friedrichshafen | Linearverschieblicher arbeitsarm, insbesondere fuer handhabungsgeraete |
| WO1999044639A1 (en) * | 1998-03-03 | 1999-09-10 | Yamanouchi Pharmaceutical Co., Ltd. | Remedies for brain infarction |
| WO2000020001A1 (en) * | 1998-10-02 | 2000-04-13 | Novartis Ag | Mglur5 antagonists for the treatment of pain and anxiety |
| GB9823847D0 (en) * | 1998-11-02 | 1998-12-23 | Lilly Co Eli | Pharmaceutical compounds |
| EP1074549B1 (en) * | 1999-08-06 | 2003-11-19 | F. Hoffmann-La Roche Ag | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors |
| DE60006618T2 (de) * | 1999-08-06 | 2004-09-23 | F. Hoffmann-La Roche Ag | Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten |
-
2001
- 2001-12-11 MX MXPA03005515A patent/MXPA03005515A/es active IP Right Grant
- 2001-12-11 BR BR0116378-7A patent/BR0116378A/pt not_active IP Right Cessation
- 2001-12-11 PT PT01271999T patent/PT1345609E/pt unknown
- 2001-12-11 KR KR1020037008488A patent/KR100545906B1/ko not_active Expired - Fee Related
- 2001-12-11 DK DK01271999T patent/DK1345609T3/da active
- 2001-12-11 ES ES01271999T patent/ES2243400T3/es not_active Expired - Lifetime
- 2001-12-11 DE DE60111568T patent/DE60111568T2/de not_active Expired - Lifetime
- 2001-12-11 JP JP2002552562A patent/JP4077319B2/ja not_active Expired - Fee Related
- 2001-12-11 WO PCT/EP2001/014527 patent/WO2002051418A1/en not_active Ceased
- 2001-12-11 AU AU2002216095A patent/AU2002216095B2/en not_active Ceased
- 2001-12-11 AT AT01271999T patent/ATE297734T1/de active
- 2001-12-11 CN CNB018222099A patent/CN1260226C/zh not_active Expired - Fee Related
- 2001-12-11 CA CA2432077A patent/CA2432077C/en not_active Expired - Fee Related
- 2001-12-11 EP EP01271999A patent/EP1345609B1/en not_active Expired - Lifetime
- 2001-12-12 US US10/020,680 patent/US6586422B2/en not_active Expired - Fee Related
- 2001-12-20 AR ARP010105926A patent/AR032379A1/es unknown
-
2003
- 2003-06-11 ZA ZA200304557A patent/ZA200304557B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004517850A5 (enExample) | ||
| JP2020183410A5 (enExample) | ||
| AU757252B2 (en) | Imidazolone anorectic agents: I. acyclic derivatives | |
| JP2010509356A5 (enExample) | ||
| JP2007520520A5 (enExample) | ||
| JP2007520440A5 (enExample) | ||
| JP2004536869A5 (enExample) | ||
| JP2004518763A5 (enExample) | ||
| JP2006507355A5 (enExample) | ||
| JP2005522438A5 (enExample) | ||
| JP2009538873A5 (enExample) | ||
| JP2002520316A5 (enExample) | ||
| JP2004517099A5 (enExample) | ||
| JP2005526836A5 (enExample) | ||
| JP2005530811A5 (enExample) | ||
| JP2008505107A5 (enExample) | ||
| JP2005511697A5 (enExample) | ||
| JP2002030084A5 (enExample) | ||
| JP2005511594A5 (enExample) | ||
| EP2247601A1 (en) | Thiazopyrimidinones and uses thereof | |
| JP2003518106A5 (enExample) | ||
| JP2002526410A5 (enExample) | ||
| RU2374228C2 (ru) | Производные 4-фенилпиперидина в качестве ингибиторов ренина | |
| JP2003507380A5 (enExample) | ||
| CA2432077A1 (en) | Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists |